Daiichi Sankyo Co., Ltd. (4568)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Daiichi Sankyo Co., Ltd. (4568)
Go deeper and ask any question about 4568
Company Performance
Current Price
as of Sep 17, 2024$35.34
P/E Ratio
41.55
Market Cap
$67.15B
Description
Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals. Its products include drugs for the field of oncology such as Trastuzumab deruxtecan, Anti-HER3-ADC, Quizartinib, Milademetan, Valemetostat, Pexidartinib, Edoxaban, Prasugel, and Microgabalin. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan.
Metrics
Overview
- HQTokyo, TY
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- Ticker4568
- Price$35.33705-3.17%
Trading Information
- Market Cap$67.15B
- Float86.49%
- Average Daily Volume (1m)5,106,548
- Average Daily Volume (3m)4,620,885
- EPS$119.55
Company
- Revenue$1.69T
- Rev Growth (1yr)24.32%
- Net Income$85.38B
- Gross Margin78.21%
- EBITDA Margin18.78%
- EBITDA$81.91B
- EV$9.88T
- EV/Revenue5.86
- P/E41.55
- P/S5.64
Documents
Factset Street Account
Factset